QUEBEC CITY,
May 21, 2013 /CNW Telbec/ - Aeterna
Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"),
announced today that it has entered into an "At Market" Issuance
("ATM") Sales Agreement, dated May 21,
2013, with MLV & Co. LLC ("MLV"), under which the
Company may, at its discretion, from time to time during the term
of the sales agreement, sell up to a maximum of 2.5 million
of its common shares through ATM issuances on the NASDAQ Stock
Market up to an aggregate amount of US$4.6
million. MLV will act as sales agent for any sales made
under the ATM. The common shares will be sold at market prices
prevailing at the time of the sale of common shares, and, as a
result, prices may vary.
In connection with the execution of the ATM Sales
Agreement with MLV, the Company will file shortly a prospectus
supplement to its U.S. shelf prospectus, dated June 8, 2012, forming part of its U.S.
registration statement on Form F-10 with the United States
Securities and Exchange Commission ("SEC") as well as a prospectus
supplement to its Canadian final base shelf prospectus dated
June 8, 2012.
The U.S. shelf prospectus and, when filed, the
supplement thereto, will be available on the SEC's website
(www.sec.gov) and the Canadian final base shelf prospectus and,
when filed, the supplement thereto, will be available on the
SEDAR website maintained by the Canadian Securities Administrators
at www.sedar.com. Alternatively, MLV will provide copies of the
U.S. documents upon request by contacting MLV & Co. LLC,
Attention: Randy Billhardt, 1251
Avenue of the Americas, 41st Floor, New York, NY 10020, or by calling
212-542-5882, while copies of the Canadian documents may be
obtained by contacting the Company's Investor Relations department
directly by calling (418) 652-8525, ext. 265.
This press release does not and shall not
constitute an offer to sell or the solicitation of an offer to buy
any of the common shares, nor shall there be any sale of the common
shares in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of such state or
jurisdiction.
About Aeterna Zentaris Inc.
Aeterna Zentaris is an oncology and endocrinology
drug development company currently investigating treatments for
various unmet medical needs. The Company's pipeline encompasses
compounds at all stages of development, from drug discovery through
to marketed products. For more information please visit
www.aezsinc.com.
SOURCE Aeterna Zentaris Inc.